Long Position on VRX @ $104.00 on 9/23/2013 (Momentum)

Valeant Pharmaceuticals International (VRX) is a specialty pharmaceutical company.

The firm develops, manufactures, and markets pharmaceutical products and medical devices in the areas of neurology, dermatology, and branded generics.

It offers dermatology products, such as Zovirax Ointment, Xerese, Retin-A Micro, Elidel, Carac, Acanya gel, Sculptra and Sculptra Aesthetic, Atralin, Solodyn, Zyclara, Ziana, Vanos, Restylane family of products, and Dysport; over-the-counter (OTC) products, including CeraVe and AcneFree; dentistry products, such as Arestin and Teeth Whitening System; ophthalmology products, including Timoptic, Timoptic, Macugen, and Visudyne; and neurology and other products, such as Wellbutrin XL and Xenazine in the United States. The company also provides pharmaceutical products, including Tiazac XC, Wellbutrin XL, Zovirax, Benzaclin, and Penlac; and Cold-FX, an OTC product in Canada, as well as Duromine/Metermine, Difflam, Duro-Tuss, and Rikodeine in Australia. In addition, it offers a range of treatments, including antibiotics, treatments for cardiovascular and neurological diseases, dermatological products, and diabetic therapies, as well as a range of various OTC products in Europe; and products for a range of therapeutic classes, including vitamin deficiency, antibacterials, and dermatology in Mexico and Brazil.  

Shares have formed a bullish "cup & handle" and higher share prices are expected for this stock.

52-Week Trading Range: $52.50 - $106.98

Last Trade: $104.00

Stop Loss: $98.80

Target Price: $114.40

Updates

10/21/2013 9:37:08 AM

VRX reached our target price. If you elect to stay in the stock, raise your stop loss to $113.75 to protect your gains.

Position closed on 10/21/2013 at price of $114.70 with a 10.29% gain in 28 days.

Back to Portfolio